Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment

In their article, Cheng et al.1 reveal that NEK2 loss reshapes the tumor microenvironment, reducing tumor-associated macrophages and decreasing T cell exhaustion. They show that this ultimately favors the immune system's anti-cancer response in multiple myeloma.

Automated summary

In their study, Cheng et al.1 demonstrate that NEK2 loss can alter the tumor microenvironment, leading to a reduction in tumor-associated macrophages and alleviating T cell exhaustion. This ultimately enhances the immune system's ability to fight against multiple myeloma.